CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of acute myeloid leukemia.
  
  LEARNING OBJECTIVES

  • Recall emerging research data affecting the clinical management of various forms of AML, and as applicable, adapt treatment algorithms based on these findings.
  • Analyze patient-specific factors and available trial data guiding the selection of induction therapy for primary and secondary AML to optimize clinical and quality-of-life outcomes.
  • Describe the biological rationale for and available research findings with Bcl-2-targeted therapy for patients with AML, and appraise the current and future role of this strategy in clinical care.
  • Reflect on available research with approved FLT3 inhibitors, and use this information to guide the clinical management of newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Understand published data with and the role of available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or IDH2 mutation, and incorporate these agents into management algorithms.
  • Recognize the scientific justification for the development of menin inhibitors for certain genetically defined subsets of AML, and consider available research findings with and the current and future role of these novel agents.
  • Recollect the mechanisms of action of, available data with and ongoing clinical trials evaluating other novel agents and approaches for AML, and appropriately counsel patients about the potential benefits of participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.75 (audio) and 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHAML24/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASHAML24/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHAML24/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASHAML24.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Alexander Perl, MD
  Associate Professor of Medicine
  Perelman School of Medicine
  Member, Leukemia Program
  Abramson Cancer Center
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Advisory Committees: Aptose Biosciences, Astellas, Bristol Myers Squibb, Curis Inc, Daiichi Sankyo Inc, Rigel Pharmaceuticals Inc, Schrödinger, Syndax Pharmaceuticals; Consulting Agreements: Astellas, Daiichi Sankyo Inc, Foghorn Therapeutics; Contracted Research: Astellas, Daiichi Sankyo Inc, Syndax Pharmaceuticals; Data and Safety Monitoring Board/Committee: Foghorn Therapeutics; Nonrelevant Financial Relationships: Beat AML LLC, Leukemia & Lymphoma Society.
  
  Richard M Stone, MD
  Lunder Family Chair in Leukemia
  Chief of Staff
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Amgen Inc, Aptevo Therapeutics, AvenCell, BerGenBio ASA, Bristol Myers Squibb, Cellarity, CTI BioPharma, a Sobi Company, Curis Inc, Daiichi Sankyo Inc, Ensem Therapeutics, GlycoMimetics Inc, GSK, Hemavant, Jazz Pharmaceuticals Inc, Kura Oncology, LAVA Therapeutics, Ligand Pharmaceuticals, Redona Therapeutics, Rigel Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Aptevo Therapeutics, Ipsen Biopharmaceuticals Inc, Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc.
  
  Eunice S Wang, MD
  Chief, Leukemia/Benign Hematology Service
  Professor of Oncology, Department of Medicine
  Roswell Park Comprehensive Cancer Center
  Buffalo, New York
  
  Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Gilead Sciences Inc, GSK, ImmunoGen Inc, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Kura Oncology, Novartis, QIAGEN, Rigel Pharmaceuticals Inc, Ryvu Therapeutics, Schrödinger, Servier Pharmaceuticals LLC, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc; Consulting Agreement: Kura Oncology; Contracted Research: Arog Pharmaceuticals Inc, Astellas, Biomea Fusion, Cellectis, ImmunoGen Inc, Kura Oncology, Pfizer Inc, Precigen Inc, Sumitomo Dainippon Pharma Oncology Inc, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Gilead Sciences Inc; Speakers Bureaus: Astellas, Daiichi Sankyo Inc, DAVA Oncology, Pfizer Inc; Nonrelevant Financial Relationship: UpToDate (section editor).
  
  Andrew H Wei, MBBS, PhD
  Professor, Department of Haematology
  Peter MacCallum Cancer Centre and Royal Melbourne Hospital
  University of Melbourne
  Walter and Eliza Hall Institute of Medical Research
  Melbourne, Australia
  
  Advisory Committees: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc, Roche Laboratories Inc, Servier Pharmaceuticals LLC; Consulting Agreements: AbbVie Inc, Aculeus Therapeutics, Novartis, Servier Pharmaceuticals LLC, Shoreline Biosciences; Contracted Research: AbbVie Inc, Amgen Inc, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Data and Safety Monitoring Board/Committee: HOVON; Speakers Bureaus: AbbVie Inc, Astellas, Bristol Myers Squibb, Novartis, Servier Pharmaceuticals LLC; Nonrelevant Financial Relationship: Prof Wei is an employee of the Walter and Eliza Hall Institute (WEHI). WEHI receives milestone and royalty payments related to the development of venetoclax. Current and past employees of WEHI may be eligible for financial benefits related to these payments. Prof Wei receives such a financial benefit.
  
  MODERATOR
  Eytan M Stein, MD
  Chief, Leukemia Service
  Director, Program for Drug Development in Leukemia
  Associate Attending Physician
  Leukemia Service, Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Contracted Research: Astellas, Bristol Myers Squibb, Genentech, a member of the Roche Group, Syndax Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc.
  
  Release date: January 2025
  Expiration date: January 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.